Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
euroPLX 90 LisboneuroPLX 90 Lisbon
Not Confirmed
Not Confirmed
02-03 March, 2026
BIO CEO & InvestorBIO CEO & Investor
Not Confirmed
Not Confirmed
02-03 March, 2026
Clinical OutsourcingClinical Outsourcing
Not Confirmed
Not Confirmed
03-04 March, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS





Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
euroPLX 90 LisboneuroPLX 90 Lisbon
Industry Trade Show
Not Confirmed
02-03 March, 2026
BIO CEO & InvestorBIO CEO & Investor
Industry Trade Show
Not Confirmed
02-03 March, 2026
Clinical OutsourcingClinical Outsourcing
Industry Trade Show
Not Confirmed
03-04 March, 2026
Digital content

27 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260227837288/en/Guardant-Health-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635c4

19 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260219448137/en/Guardant-Health-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-2026-Outlook

03 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260203339557/en/Guardant-Health-to-Participate-in-Upcoming-Investor-Conferences

02 Feb 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260202593149/en/Largest-Published-Study-of-Molecular-Residual-Disease-MRD-in-Stage-III-Colon-Cancer-Shows-Guardant-Reveal-Blood-Test-More-Precisely-Identifies-Risk-of-Recurrence-After-Surgery-to-Support-Timely-Treatment-Decisions

29 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260129040273/en/Guardant-Health-to-Report-Fourth-Quarter-and-Full-Year-2025-Financial-Results-on-February-19-2026

22 Jan 2026
// BUSINESSWIRE
https://www.businesswire.com/news/home/20260122091904/en/Guardant-Health-Receives-FDA-Approval-for-Guardant360-CDx-as-Companion-Diagnostic-for-BRAFTOVI-encorafenib-Combination-in-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer
ABOUT THIS PAGE